Prevalence of 'borderline' values of cardiovascular risk factors in the clinical practice of general medicine in Italy: Results of the BORDERLINE study

被引：3
作者：
Tocci G. [1 ]
Ferrucci A. [1 ]
Passerini J. [1 ]
Averna M. [2 ]
Bellotti P. [3 ]
Bruno G. [4 ]
Cosentino F. [1 ]
Crepaldi G. [5 ]
Giannattasio C. [6 ]
Modena M.G. [7 ]
Nati G. [8 ]
Tiengo A. [9 ]
Trimarco B. [10 ]
Vanuzzo D. [11 ]
Volpe M. [1 ,12 ]
机构：
[1] Department of Clinical and Molecular Medicine, University of Rome Sapienza, SantAndrea Hospital, 00189 Rome, Via di Grottarossa
[2] Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo
[3] Division of Cardiology, San Paolo Hospital, Savona
[4] Department of Internal Medicine, University of Turin, Turin
[5] CNR, Institute of Neuroscience, Section on Aging, Padova
[6] Division of Clinical Medicine, Milano Bicocca University, San Gerardo Hospital, Monza
[7] Division of Cardiology, Department of Emergency and Urgency, University of Modena, Modena
[8] Italian Society of General Medicine (SIMG), Rome
[9] Department of Clinical and Experimental Medicine, University of Padova, Padova
[10] Department of Clinical Medicine, Cardiovascular and Immunological Sciences, Federico II University Hospital, Naples
[11] Cardiovascular Prevention Centre, Health Unit 4 Medio Friuli, Udine
[12] IRCCS Neuromed, Pozzilli, Isernia
来源：
High Blood Pressure & Cardiovascular Prevention | 2011年 / 18卷 / 2期
关键词：
blood pressure; borderline risk; cardiovascular prevention; cholesterol; global cardiovascular risk; glucose; high-normal risk;
D O I：
10.2165/11593420-000000000-00000
中图分类号：
学科分类号：
摘要：
Introduction: The prevalence of patients with 'borderline' levels of cardiovascular risk factors has been rarely investigated, being often reported in studies evaluating abnormal values of these parameters. The BORDERLINE study represents a pilot experience to primarily identify the prevalence of 'high-normal' conditions, such as pre-hypertension, lipid and glucose levels in the upper range of normality in the setting of general practice in Italy. Aim: The aim of this study was to evaluate the prevalence of patients with 'borderline' values of cardiovascular risk factors in Italy. Methods: Involved physicians were asked to evaluate the first 20 outpatients, consecutively seen in June 2009. Data were collected in a study-designed case-report form, in which physicians identified thresholds rather than reported absolute values of several clinical parameters. High-normal values were defined as follows: blood pressure (BP) 130-140/85-90 mmHg; total cholesterol 180-200 mg/dL; low-density lipoprotein cholesterol (LDL-C) 130-150 mg/dL; high-density lipoprotein cholesterol (HDL-C) 30-40 mg/dL in males and 40-50 mg/dL in females; triglycerides 130-150 mg/dL and fasting glucose 100-110 mg/dL. Results: Fifty-three Italian physicians provided valuable clinical data on 826 individual outpatients, among which 692 (83.7%, 377 women, mean age 60.9 ± 13.2 years, body mass index 26.6 ± 5.0 kg/m 2) were included in the present analysis. Prevalence of borderline values of systolic BP and total cholesterol levels were at least comparable with those in the normal limits of the corresponding parameters, whereas prevalence of borderline diastolic BP, LDL-C, HDL-C, triglycerides and fasting glucose levels was significantly lower than that of normal values, but higher than that of abnormal values of the corresponding parameters. Conclusions: Using this sample of healthy subjects in the setting of general practice in Italy, our results demonstrated a relatively high prevalence of borderline values of cardiovascular risk factors, which was at least comparable with that of normal, but significantly higher than that of abnormal thresholds. These preliminary findings may prompt more extensive investigations in the area of 'borderline' cardiovascular risk. This information may, in fact, potentially enable the design of more effective prevention strategies in the future to limit the burden of cardiovascular disease in the general population in Italy. © 2011 Adis Data Information BV. All rights reserved.
引用
收藏
页码：43 / 51
页数：8
相关论文
共 27 条
  • [1] Kotseva K., Wood D., De Backer G., Et al., Cardiovascular prevention guidelines in daily practice: A comparison of EUROASPIRE I, II, and III surveys in eight European countries, Lancet, 373, 9667, pp. 929-40, (2009)
  • [2] Volpe M., White paper for implementing strategies and interventions for cardiovascular prevention in Italy, High Blood Press Cardiovasc Prev 2008, 15, 2, pp. 63-73, (2008)
  • [3] Morrell J., Zeymer U., Baumgartner I., Et al., Differences in management and outcomes between male and female patients with atherothrombotic disease: Results from the REACH Registry in Europe, Eur J Cardiovasc Prev Rehabil, 18, 2, pp. 270-7, (2011)
  • [4] Volpe M., Erhardt L.R., Williams B., Managing cardiovascular risk: The need for change, J Hum Hypertens, 22, 2, pp. 154-7, (2008)
  • [5] Gaede P., Lund-Andersen H., Parving H.-H., Pedersen O., Effect of a multifactorial intervention on mortality in type 2 diabetes, New England Journal of Medicine, 358, 6, pp. 580-591, (2008)
  • [6] Gaede P., Vedel P., Larsen N., Jensen G.V.H., Parving H.-H., Pedersen O., Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes, New England Journal of Medicine, 348, 5, pp. 383-393, (2003)
  • [7] Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J., Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial, Lancet, 366,
  • [8] Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial, Lancet, 361, 9364, pp. 1149-1158, (2003)
  • [9] Manuel D.G., Lim J., Tanuseputro P., Anderson G.M., Alter D.A., Laupacis A., Mustard C.A., Preventive medicine - Revisiting Rose: Strategies for reducing coronary heart disease, British Medical Journal, 332, 7542, pp. 659-662, (2006)
  • [10] Sasamura H., Nakaya H., Julius S., Et al., The short treatment with the angiotensin receptor blocker candesartan surveyed by telemedicine (STAR CAST) study: Rationale and study design, Hypertens Res, 31, 10, pp. 1843-9, (2008)
123